Molnupiravir N-1 CAS 2346620-55-9 COVID-19 Kūlana Kiʻekiʻe
Hoʻolako Kalepa Molnupiravir a me nā Intermediates pili me ke kūlana kiʻekiʻe
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Inoa Kimia | Molnupiravir N-1 |
| Nā huaʻōlelo like | ((3aR,4R,6R,6aR)-6-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3, 4-d][1,3]dioxol-4-yl)methyl isobutyrate;Molnupiravir Intermediate;Molnupiravir Dimethyl Dioxol haumia;Molnupiravir haumia 11 |
| Helu CAS | 2346620-55-9 |
| Helu CAT | RF-PI310 |
| Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
| ʻĀpana Molekala | C16H23N3O7 |
| Kaumaha Molecular | 369.37 |
| Ka hikiwawe | Hiki ke hoʻoheheʻe ʻia ma DMSO |
| ʻO ka mānoanoa | 1.51±0.1 g/cm3 |
| Ka Mahana Hoouna | Ambient |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Keʻokeʻo a hiki i ka pauda keʻokeʻo |
| Nalo ma ka maloo | ≤1.0% |
| Koena ma ka Ignition | ≤0.20% |
| Hoʻokahi haumia | ≤0.50% |
| Huina paumaele | ≤2.0% |
| Nā Metala Kaumaha | ≤20ppm |
| Maemae | ≥98.0% |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
| Hoʻohana | Kūwaena o Molnupiravir (CAS 2349386-89-4) COVID-19 |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
ʻO Molnupiravir N-1 (CAS 2346620-55-9), ʻo ia ka mea waena o Molnupiravir (CAS 2349386-89-4) i ka mālama ʻana i ka COVID-19.ʻO Molnupiravir (EIDD-2801) kahi ʻano bioavailable waha o kahi analog ribonucleoside ikaika loa e pale ai i ka hoʻopiʻi ʻana o nā maʻi RNA lehulehu me SARS-CoV-2, ke kumu kumu o COVID-19.ʻO EIDD-2801 (7 mg/kg; po; ʻelua manawa i kēlā me kēia lā no 3.5 mau lā) e hoʻemi nui i ka ukana maʻi maʻi a me ka lōʻihi o ke kuni.ʻO ka Molnupiravir (EIDD-2801) ka hydrolyzed maikaʻi i loko o ka vivo ma hope o ka absorption, ka hopena i ka ʻike ʻana i ka NHC manuahi wale nō i loko o ka plasma.Hoʻemi ikaika ʻo EIDD-2801 i nā titers infectious MERS-CoV, viral RNA, a me pathogenesis ma lalo o nā kūlana prophylactic a me nā kūlana lapaʻau mua.ʻO ka Molnupiravir (EIDD-2801, MK-4482) he prodrug bioavailable waha o ka ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) me ka hana antiviral ākea ākea e kūʻē iā SARS-CoV-2, MERS-CoV, ʻO SARS-CoV, a me ka mea kumu kumu o COVID-19.
